Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page, with its footer revision changing from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-03T17:53:57.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from “Artificial Intelligence” to “Super Intelligence” terminology, and the site revision changes from v3.7.1 to v3.7.2. The study page continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-20T19:11:09.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T19:47:21.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Access to the study page now shows a 403 Forbidden error instead of the study record, effectively blocking the main content while the site chrome remains visible.
    Difference
    17%
    Check dated 2026-09-22T20:50:50.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.6 to v3.7.0, indicating a routine update to the site or document version.
    Difference
    0.0%
    Check dated 2026-09-15T20:35:52.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5.
    Difference
    0.0%
    Check dated 2026-09-01T18:20:15.000Z thumbnail image

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.